Research Highlights

Purdue Pharma’s 2010 reformulation of OxyContin as an abuse-resistant pill was supposed to be a breakthrough in battling the burgeoning opioid epidemic. Purdue executives and policymakers touted the reformulation as a way to dampen the supply of abusable drugs, thereby reducing opioid addiction and death. Nearly a decade later, it appears that the policy had several serious […]

The intersection of criminal justice-involved populations and people who use substances makes criminal justice outcomes particularly significant for estimating the economic impact of substance use disorder interventions. New National Institute on Drug Abuse (NIDA) HEAL initiative funding opportunities in response to the opioid crisis include integrated studies that will develop, test, and validate evidence-based approaches to preventing […]

Late last year, the Centers for Disease Control and Prevention (CDC) announced that more than 70,000 people died from drug overdoses in 2017, a 9.6% increase from 2016. Deaths continue to soar, even as states and health systems implement policies to curb the overprescribing of opioids that led to the epidemic in the first place. It’s hard […]

One key strategy in reducing deaths from the opioid epidemic is to improve access to existing evidence-based treatments. Two new economic studies by CHERISH Investigators Drs. Sean Murphy, Kathryn McCollister, and Bruce Schackman can help providers, patients, and payers sort through alternative pharmacotherapies to prevent opioid relapse. The US Food and Drug Administration has approved […]

Despite little evidence, some commentators and policymakers have argued that Medicaid expansion has fueled the opioid epidemic by increasing access to prescription opioids. But a growing number of studies refute this theory, and instead suggest that Medicaid expansion reduces mortality from drug overdoses and increases access to drug treatment. The latest such evidence comes from LDI Fellows Paula Chatterjee and Atheendar Venkataramani, who analyzed […]

A recent study in Health Affairs by CHERISH Research Affiliate Dr. Yuhua Bao and CHERISH investigators Dr. Zachary Meisel and Dr. Bruce Schackman examined the impact of prescription drug monitoring program policies on high-risk opioid prescriptions. Prescription drug monitoring programs (PDMPs) are statewide databases of controlled substances dispensed at retail pharmacies. Currently, all states and Washington D.C. except Missouri […]

As the country faces an unprecedented opioid epidemic, there’s an active national conversation about how inappropriate prescribing contributes to chronic opioid use, misuse, and addiction. Evidence is rapidly evolving to inform the policy debate, especially regarding best practices for prescribing in acutely painful conditions, like an injury or surgery, but the evidence is less clear […]

The National Institutes of Health (NIH) announced the Helping to End Addiction Long-Term (HEAL) Initiative in spring 2018. This trans-NIH initiative will provide an additional $500 million in funding. The HEAL initiative will target two priority areas for research: to improve treatments for opioid misuse and addiction and to enhance pain management. The initiative will […]

CHERISH investigators recently published findings and lessons learned from the implementation of CHERISH’s nationwide consultation service. The CHERISH Consultation Service is free to researchers, regardless of affiliation, whose work aligns with CHERISH’s mission and who would like to incorporate an economic analysis into their research. Interested researchers complete and submit a consultation request form online and are subsequently connected […]

Hepatitis C Virus (HCV) is one of the leading causes of infectious disease deaths in the United States. Injection drug use is a common route of HCV transmission and the annual number of reported cases continues to rise due to the opioid epidemic. Previous HCV treatment regimens had severe side effects and limited efficacy, but […]

Key Findings Setting a low quantity of opioid tablets as the default option in electronic medical record prescribing orders may “nudge” clinicians to prescribe fewer opioids. When two emergency departments implemented a 10-tablet default instead of a manual entry, the proportion of 10-tablet prescriptions written more than doubled, from 20.6% to 43.3%. Conversely, 20-tablet prescriptions […]

An estimated 13 million people in the US report non-medical use of prescription opioids in the previous year, of whom 2.5 million have opioid use disorders that require treatment. Only 10% of those with an opioid use disorder receive any type of specialty substance use treatment. Even fewer have access to pharmacotherapy including methadone maintenance, buprenorphine, or […]